PG&E is executing a capital plan exceeding $70 billion through 2030, aiming for high single-digit EPS growth and a $2.33 per share EPS target by 2030. The company plans a 4% dividend yield and 9% annual rate base growth, funding expansion through debt rather than new equity to avoid diluting shareholders. Despite wildfire risks, operational improvements and undergrounding efforts have eliminated structure losses in the past four years. PG&E aims to keep customer bills at or below inflation while delivering substantial shareholder returns.
PG&E's wildfire risk management and capital plan provide context for utility sector investors. For readers following utilities, here is Pluang's market snapshot as of Sep 15, 2026 14:42 WIB: Among 23 priced US utilities stocks, 10 rose and 12 fell today. Notable movers include NRG at USD 108.20 down 4.64%, BEP at USD 29.49 down 2.96%, and FLUX at USD 0.56 down 1.78%.
Panda Bundler, developed by PandaBoost, is a web application designed to help teams manage wallets and trading operations after launching tokens on Robinhood Chain, specifically with the Pons launchpad. It provides a unified workspace to monitor wall...
Filecoin (FIL) fell 11.53% to $0.887 on September 15, 2026, following a technical correction after a 40% price surge from its all-time low of $0.614 in August. No negative news or fundamental issues triggered the drop; it reflects profit-taking and m...
Meta Platforms has received a Buy rating at a price of $648, with a valuation target of $920 by 2029 based on normalized earnings per share and a 20x multiple. The company has demonstrated that AI improvements have enhanced advertising engagement and...
Bitcoin trades just above its 30-day low of $76,429, down 1.3% in 24 hours, reflecting cautious institutional flows into spot BTC ETFs like BlackRock IBIT and Fidelity FBTC. The total crypto market cap fell 2.6% to $2.64 trillion with $89 billion vol...
The Harbor Health Care ETF returned 15.30% in the second quarter of 2026, led by strong gains in biotechnology stocks fueled by clinical data and merger activity. Pharmaceutical stocks lagged due to the ETF's lower exposure to Eli Lilly, a major benc...
